Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary Disease
A legfontosabb adatok
- Ki végzi
- Hofseth Biocare ASA
- Hol
- Norvégia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Visszavonva
- Kezdés
- 2025. júl.
- Várható befejezés
- 2027. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- CARDIO®
- Placebo
- A regiszteradat frissítve
- 2025. szeptember 26.
- Miért állt le
- The study was terminated before recruitment began due to administrative decision.
Ki vehet részt
- Életkor
- 40 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Diagnosed and under treatment for COPD with regular maintenance therapy
- Postbronchodilator FEV1-FVC ratio less than 0.70 the last 3 months
- FEV1<90%
- Current smoker or ex-smoker at least 10 pack-years
- COPD Assessment Test score level (CAT) ≥10
- Patients with overlapping COPD and asthma disease may be included
- Speaks fluent Norwegian
- Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulation
Ki nem vehet részt
- Treatment with oral steroid < 1 month prior to baseline visit
- Oral/intravenous antibiotics < 1 month prior to baseline visit
- Immunosuppressant therapy such as Cyclosporine and Azathioprine
- Consumption regularly of fish/krill oil (liquid, capsule, powder) as an oral supplement < 1 month prior baseline visit
- Evidence and/or diagnose of clinically significant uncontrolled non-pulmonary disease; Myocardial infarction or stroke within the last 12 months, angina pectoralis diagnosed < 3 months or unstable angina; Stage 4 of Congestive Heart Failure according to The New York Heart Association (NYHA) (severe heart failure with poor outcome and decreased survival rate); Cancer diagnosed within the last 12 months (except basal cell carcinoma of the skin), and/or ongoing active cancer therapy; Severe liver disease; Severe autoimmune diseases requiring immunosuppressant treatment
- Pulmonary fibrosis, interstitial lung disease, pulmonary hypertension, sarcoidosis, or significant bronchiectasis
- Known fish or shellfish allergy
- Inflammatory bowel disease (Crohn's disease, UC, microscopic colitis), celiac disease, malabsorption, lactose intolerance
- Severe cognitive impairment where the participants are not able to comply to protocol
- Participant in any other clinical study
- Any reason why, in the opinion of the investigator, the patient cannot participate, or is not in the patient's best interest
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Research has over decades showed that marine food carries nutritional characteristics that promote human health. As seen in epidemiological studies and based on in vitro and in vivo studies, it is hypothesized that unrefined salmon oil as dietary supplement have anti-inflammatory effect. However, there is sufficient preliminary data to indicate bioactive compounds effect for clinical use, and further clinical trials investigating effect are needed. This trial will investigate the potential anti-inflammatory effect and reduction in the risk of cardio artery disease in patients diagnosed with chronic obstructive disease, COPD.
A vizsgálat 2 csoportja
- Best Standard of Care + CARDIO®Már használt kezelés, összehasonlításként
6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides.
Kezelés: CARDIO®
- Best Standard of Care + PlaceboPlacebo, összehasonlításként
6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
Kezelés: Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized Controlled Trial Investigating the Efficacy and Safety of Cardio® in Patient With Chronic Obstructive Pulmonary Disease
- A regiszteradat frissítve
- 2025. szeptember 26.